Article

Genomic Insights Guiding Personalized First-Line Immunotherapy Response in Lung and Bladder Tumors

2024-10-29

Abstract excerpt

<h4>ABSTRACT</h4> Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, particularly in advanced non-small cell lung cancer (NSCLC) and muscle-invasive bladder cancer (MIBC). However, identifying reliable predictive biomarkers for ICI response remains a significant challenge. In this study, we analyzed real-world cohorts of advanced NSCLC and MIBC patients treated with ICIs as first-line thera...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6bed6a08-1a15-51eb-bd5b-5e73d0cbad35
DOI: 10.1101/2024.10.25.620156

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic Insights Guiding Personalized First-Line Immunotherapy Response in Lung and Bladder TumorsDOI 10.1101/2024.10.25.620156Read

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read

Pan-cancer analysis of tumor mutational burden and homologous recombination DNA damage repair by targeted next-generation sequencingSemantic proximity Read

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read

Somatic mutations in homologous recombination pathway predict favorable prognosis after immunotherapy across multiple cancer typesSemantic proximity Read

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read

Recurrent somatic mutations as predictors of immunotherapy response.Semantic proximity Read

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerSemantic proximity Read

Prospective Germline Exome and Machine Learning-Based Risk Score Identify Predictive and PrognosticBiomarkers of Immunotherapy Outcomes in Advanced Non-Small Cell Lung CancerSemantic proximity Read

Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatmentSemantic proximity Read